BIOYF (Biosyent) Other Net Income (Loss) : $-0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Biosyent Other Net Income (Loss)?

Biosyent's Other Net Income (Loss) for the three months ended in Mar. 2025 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.00 Mil.

Biosyent's quarterly Other Net Income (Loss) stayed the same from Sep. 2024 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then increased from Dec. 2024 ($-0.00 Mil) to Mar. 2025 ($0.00 Mil).

Biosyent's annual Other Net Income (Loss) increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Biosyent Other Net Income (Loss) Historical Data

The historical data trend for Biosyent's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Other Net Income (Loss) Chart

Biosyent Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Biosyent Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Biosyent Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Biosyent Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Biosyent's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

RX:Canada

Address

2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1

Website

http://www.biosyent.com

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.